TrackPaw Secures €2.3M to Revolutionize Preclinical Research with AI-Powered Monitoring
TrackPaw Scientific, the Lund-based startup in the field of preclinical research, announced recently it had successfully closed a € 2.3 million funding round. The round was co-led by FSG Fund II and Industrifonden, two prominent investors in life science and technology, with an additional € 0.5 million contributed by existing shareholders.
This funding will enable TrackPaw to transition from its current beta stage with select global pharmaceutical partners to a full commercial launch in the Nordics in the second half of 2026.
“The investment truly symbolizes an unmet need in the market that we have a solution for. We’re now ready to emerge from stealth mode and work towards satisfying the hungry preclinical and breeding market with 24/7 cutting-edge insights.”
said Liza T. Albrektson, CEO and Co-founder of TrackPaw Scientific.
Founded in 2022 and headquartered in Lund, Sweden, TrackPaw Scientific is tackling one of the major challenges in clinical development: the high failure rate of over 90% due to subjective and inconsistent conclusions from animal-based preclinical studies. By integrating machine learning and sensor technology, TrackPaw monitors animal behavior and weight in real time, providing scientists with objective, high-resolution data across a wide range of disease areas. This innovation leads to more robust study outcomes, improved animal welfare, and faster access to effective new medicines.
“We believe TrackPaw has assembled an outstanding team and a truly remarkable product that stands to transform the landscape of preclinical research. By delivering more reliable and sustainable data, they not only enhance the quality of scientific outcomes but also drive significant cost savings for major pharma players. This isn’t just an exciting initiative; it’s a game changer that sets a new standard for the industry and elevates animal welfare to new heights.”
said Alexander Jöndell, Partner at Fåhraeus Startup & Growth.
With this capital injection, TrackPaw Scientific will accelerate its efforts to achieve commercial launch readiness in the Nordics by the second half of 2026. The company is developing a groundbreaking solution for digital monitoring and analysis in preclinical research.
“We’re excited to back TrackPaw as they tackle one of the biggest bottlenecks in preclinical research. Their innovative approach has the potential to improve data quality, accelerate drug development, and raise animal welfare standards—all of which are critical for the future of life science.”
said Jonas Jendi, Senior Investment Director at Industrifonden.
The post TrackPaw Secures €2.3M to Revolutionize Preclinical Research with AI-Powered Monitoring appeared first on Øresund Startups.